Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for iBio (IBIO) over the last 17 years, with Q4 2025 value amounting to $28.7 million.

  • iBio's Cash & Equivalents rose 30912.33% to $28.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $28.7 million, marking a year-over-year increase of 30912.33%. This contributed to the annual value of $8.6 million for FY2025, which is 3960.59% down from last year.
  • iBio's Cash & Equivalents amounted to $28.7 million in Q4 2025, which was up 30912.33% from $28.1 million recorded in Q3 2025.
  • In the past 5 years, iBio's Cash & Equivalents ranged from a high of $84.6 million in Q1 2021 and a low of $1.5 million during Q3 2023
  • Over the past 5 years, iBio's median Cash & Equivalents value was $10.5 million (recorded in 2022), while the average stood at $22.9 million.
  • In the last 5 years, iBio's Cash & Equivalents surged by 74289.84% in 2021 and then plummeted by 9057.26% in 2022.
  • Quarter analysis of 5 years shows iBio's Cash & Equivalents stood at $39.2 million in 2021, then plummeted by 90.57% to $3.7 million in 2022, then dropped by 24.57% to $2.8 million in 2023, then surged by 151.61% to $7.0 million in 2024, then surged by 309.12% to $28.7 million in 2025.
  • Its last three reported values are $28.7 million in Q4 2025, $28.1 million for Q3 2025, and $8.6 million during Q2 2025.